Sbir phase II topic 275, "development of generic trastuzumab for the treatment of breast cancer."

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201200045C
Awardee
Awarding agency
Obligated
$2,499,488

Award facts

Opportunity
Contract value 100% obligated
$2,499,488.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541711 Research and Development in Biotechnology
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Cambridge, MA 02138, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 3 $0
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $2,499,488

Quick answers

Who was awarded contract HHSN261201200045C?

HHSN261201200045C was awarded to STC Biologics, Inc. by National Cancer Institute (National Institutes of Health) on September 28, 2012.

How much is contract HHSN261201200045C worth?

The government has obligated $2,499,488 on HHSN261201200045C.

Was contract HHSN261201200045C competed?

The extent of competition for HHSN261201200045C was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award